GeNeuro Overview
- Year Founded
-
2006

- Status
-
Public
- Employees
-
19

- Stock Symbol
-
GNRO

- Share Price
-
$0.15
- (As of Friday Closing)
GeNeuro General Information
Description
GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases. The company's therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family (W-ENV).
Contact Information
Website
www.geneuro.comCorporate Office
- 3, Chemin du Pré-Fleuri
- Plan-les-Ouates
- 1228 Geneva
- Switzerland
Corporate Office
- 3, Chemin du Pré-Fleuri
- Plan-les-Ouates
- 1228 Geneva
- Switzerland
GeNeuro Timeline
GeNeuro Stock Performance
As of 14-Feb-2025, GeNeuro’s stock price is $0.15. Its current market cap is $4.33M with 29.6M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$0.15 | $0.13 | $0.04 - $2.56 | $4.33M | 29.6M | 450K | -$0.64 |
GeNeuro Financials Summary
As of 31-Dec-2023, GeNeuro has a trailing 12-month revenue of null.
In Thousands, USD |
TTM 31-Dec-2023 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 35,875 | 35,875 | 33,408 | 87,204 |
Revenue | 0 | 0 | 0 | 0 |
EBITDA | (15,728) | (15,728) | (12,529) | (7,708) |
Net Income | (15,968) | (15,968) | (12,827) | (8,061) |
Total Assets | 7,032 | 7,032 | 12,301 | 14,198 |
Total Debt | 14,776 | 14,776 | 7,486 | 4,246 |
GeNeuro Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
GeNeuro Comparisons
Industry
Financing
Details
GeNeuro Competitors (50)
One of GeNeuro’s 50 competitors is CRISPR Therapeutics, a Formerly VC-backed company based in Zug, Switzerland.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland | ||||
Senti Bio | Formerly VC-backed | South San Francisco, CA | ||||
Alzheon | Venture Capital-Backed | Framingham, MA | ||||
Quince Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
Alzinova | Corporation | Gothenburg, Sweden |
GeNeuro Patents
GeNeuro Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
CA-3185024-A1 | Anti-herv-w envelope protein antibody for use in the treatment of psychotic diseases | Pending | 28-May-2020 | ||
EP-4157871-A1 | Anti-herv-w envelope protein antibody for use in the treatment of psychotic diseases | Pending | 28-May-2020 | ||
EP-3916015-A1 | Anti-herv-w envelope protein antibody for use in the treatment of psychotic diseases | Inactive | 28-May-2020 | ||
AU-2021281054-A1 | Anti-herv-w envelope protein antibody for use in the treatment of psychotic diseases | Pending | 28-May-2020 | ||
US-20240301040-A1 | Anti-herv-w envelope protein antibody for use in the treatment of psychotic diseases | Pending | 28-May-2020 | C07K16/1036 |
GeNeuro Signals
GeNeuro Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
GeNeuro ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile

Pharmaceuticals
Industry
Rank
Percentile

Biotechnology
Subindustry
Rank
Percentile

GeNeuro FAQs
-
When was GeNeuro founded?
GeNeuro was founded in 2006.
-
Where is GeNeuro headquartered?
GeNeuro is headquartered in Geneva, Switzerland.
-
What is the size of GeNeuro?
GeNeuro has 19 total employees.
-
What industry is GeNeuro in?
GeNeuro’s primary industry is Drug Discovery.
-
Is GeNeuro a private or public company?
GeNeuro is a Public company.
-
What is GeNeuro’s stock symbol?
The ticker symbol for GeNeuro is GNRO.
-
What is the current stock price of GeNeuro?
As of 14-Feb-2025 the stock price of GeNeuro is $0.15.
-
What is the current market cap of GeNeuro?
The current market capitalization of GeNeuro is $4.33M.
-
Who are GeNeuro’s competitors?
CRISPR Therapeutics, Senti Bio, Alzheon, Quince Therapeutics, and Alzinova are some of the 50 competitors of GeNeuro.
-
What is GeNeuro’s annual earnings per share (EPS)?
GeNeuro’s EPS for 12 months was -$0.64.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »